JPMorgan analyst Brian Cheng raised the firm’s price target on Revolution Medicines (RVMD) to $82 from $71 and keeps an Overweight rating on the shares. JPMorgan also added the shares to its Analyst Focus List as a growth idea. While the company’s Q3 report seems like a “non-event,” it is making strategic moves to position the entire portfolio to “win in the long run,: the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $73 from $72 at H.C. Wainwright
- Revolution Medicines Reports Q3 2025 Financial Results
- Revolution Medicines: Strategic Advancements and Promising Pipeline in PDAC Treatment Justify Buy Rating
- Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements
- Revolution Medicines reiterates FY25 GAAP net loss guidance